Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

被引：13

作者：

Griguolo, Gaia ^{[1
,2
]}

Dieci, Maria Vittoria ^{[1
,2
]}

Pare, Laia ^{[3
,4
]}

Miglietta, Federica ^{[1
,2
]}

Generali, Daniele Giulio ^{[5
]}

Frassoldati, Antonio ^{[6
]}

Cavanna, Luigi ^{[7
]}

Bisagni, Giancarlo ^{[8
]}

Piacentini, Federico ^{[9
]}

Tagliafico, Enrico ^{[10
]}

Cagossi, Katia ^{[11
]}

Ficarra, Guido ^{[12
]}

Prat, Aleix ^{[3
,4
]}

Conte, Pierfranco ^{[1
,2
]}

Guarneri, Valentina ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] Ist Oncol Veneto IOV IRCCS, Div Oncol 2, Padua, Italy

[3] Hosp Clin Barcelona, IDIBAPS, Div Oncol, Barcelona, Spain

[4] SOLTI Breast Canc Res Grp, Barcelona, Spain

[5] AO Ist Ospitalieri Cremona, Multidisciplinary Unit Breast Pathol, Cremona, Italy

[6] S Anna Univ Hosp, Dept Morphol Surg & Expt Med, Clin Oncol, Ferrara, Italy

[7] Piacenza Gen Hosp, Dept Hematol & Oncol, Oncol Unit, Piacenza, Italy

[8] Azienda Unita Sanit Locale IRCCS Reggio Emil, Dept Oncol & Adv Technol, Oncol Unit, Reggio Emilia, Italy

[9] Univ Hosp Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Modena, Italy

[10] Univ Modena & Reggio Emilia, Ctr Genome Res, Modena, Italy

[11] Ramazzini Hosp, Breast Unit, Carpi, Italy

[12] Azienda Osped Univ Policlin Modena, Dept Pathol, Modena, Italy

来源：

NPJ BREAST CANCER | 2021年 / 7卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT; THERAPY;

D O I：

10.1038/s41523-021-00223-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

引用

页数：5

共 50 条

[41] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, Aki
Henry, N. Lynn
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
[42] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
Schwartzberg, Lee S.
Kiedrowski, Lesli A.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[43] Protein-protein interaction of HER2 predicts the prognosis of hormone receptor-positive HER2-negative breast cancer
Choi, Hee Jun
Lee, Hong Won
Kim, Sangmin
Yoon, Tae-Young
Kim, Hyunwoo
Lee, Seul
Nam, Seok Jin
Kim, Seok Won
Cho, Sooyoun
Park, Yeon Hee
Lee, Jeong Eon
CANCER RESEARCH, 2020, 80 (04)
[44] Precise subtyping reveals immune heterogeneity for hormone receptor-positive breast cancer
Zhang, Mengyan
Zhang, Xingda
Ma, Te
Wang, Cong
Zhao, Jiyun
Gu, Yue
Zhang, Yan
COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 163
[45] Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive her2-negative breast cancer
Gong, Chang
Tan, Weige
Chen, Kai
You, Na
Zhu, Shan
Luo, Wei
Xie, Xinhua
Zeng, Yunjie
Ouyang, Nengtai
Li, Zhihua
Zeng, Mushen
Zhuang, ShiMei
Lau, Wan-Yee
Liu, Qiang
Su, Fengxi
Wang, Xueqin
Song, Erwei
CANCER RESEARCH, 2016, 76
[46] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, Adriana
Amaro, Carla
Verma, Sunil
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[47] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda
Erul, Enes
Seyyar, Mustafa
Gumusay, Ozge
Bayram, Ertugrul
Demirel, Burcin Cakan
Acar, Omer
Aksoy, Sercan
Baytemur, Naziyet Kose
Sahin, Elif
Cabuk, Devrim
Basaran, Gul
Paydas, Semra
Yaren, Arzu
Guven, Deniz Can
Erdogan, Atike Pinar
Demirci, Umut
Yasar, Alper
Bayoglu, Ibrahim Vedat
Hizal, Mutlu
Gulbagci, Burcu
Paksoy, Nail
Davarci, Sena Ece
Yilmaz, Funda
Dogan, Ozlem
Orhan, Sibel Oyucu
Kayikcioglu, Erkan
Aytac, Ali
Keskinkilic, Merve
Mocan, Eda Eylemer
Unal, Olcun Umit
Aydin, Esra
Yucel, Hakan
Isik, Deniz
Eren, Onder
Uluc, Basak Oyan
Ozcelik, Melike
Hacibekiroglu, Ilhan
Aydiner, Adnan
Demir, Hacer
Oksuzoglu, Berna
Cilbir, Ebru
Cubukcu, Erdem
Cetin, Bulent
Oktay, Esin
Erol, Cihan
Okutur, Sadi Kerem
Yildirim, Nilgun
Alkan, Ali
Selcukbiricik, Fatih
FUTURE ONCOLOGY, 2023, : 727 - 736
[48] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Hugo Herrscher
Michel Velten
Julie Leblanc
Michal Kalish-Weindling
Cathie Fischbach
Delphine Exinger
Xavier Pivot
Thierry Petit
Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
[49] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
Tajiri, Wakako
Nakamura, Yoshiaki
Kawasaki, Junji
Koi, Yumiko
Akiyoshi, Sayuri
Koga, Chinami
Tokunaga, Eriko
CANCER RESEARCH, 2024, 84 (09)
[50] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora
Potter, David A.
Salkeni, Mohamad A.
Silverman, Paula
Haddad, Tufia C.
Forget, Frederic
Awada, Ahmad
Canon, Jean-Luc
Danso, Michael
Lortholary, Alain
Bourgeois, Hugues
Tan-Chiu, Elizabeth
Vincent, Sylvie
Bahamon, Brittany
Galinsky, Kevin J.
Patel, Chirag
Neuwirth, Rachel
Leonard, E. Jane
Diamond, Jennifer R.
CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338

← 1 2 3 4 5 →